What kind of medicine is Aceminid and what diseases are its indications?

Asciminib (Asciminib) is a tyrosine kinase inhibitor used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML). Acemini works by specifically targeting the myristoyl pocket of ABL (called STAMP inhibitors in the scientific literature). Aceminid is available in tablet form in three strengths: 20mg, 40mg and 100mg, which can be taken by mouth once or twice a day without food. Aceminib is indicated for the treatment of the following adult patients:

1. Newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) in chronic phase (CP); this indication was approved under accelerated approval based on major molecular response rate.

2. Ph+CML has been treated in CP before;

3. Ph+CML in CP withT315I mutation.

The active substance in asciminibasciminib is a tyrosine kinase inhibitor (TKI), which means it blocks an enzyme called tyrosine kinase. In Ph+CML, the body produces large numbers of abnormal white blood cells. Aceminib specifically blocks the action of the BCR::ABL1 tyrosine kinase produced by these cells, thereby preventing them from dividing and growing.

Aceminid is only available by prescription, and treatment must be initiated and supervised by a physician experienced in the diagnosis and treatment of leukemia. If certain side effects occur, your doctor may interrupt treatment and reduce the dose. Treatment may be discontinued if the patient cannot tolerate reduced dose therapy. Common adverse reactions include musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea; serious adverse reactions may also occur, including bone marrow suppression, pancreatic toxicity, hypertension, hypersensitivity reactions, and cardiovascular toxicity.